Century Therapeutics (IPSC) Competitors $0.58 -0.02 (-3.40%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.58 0.00 (-0.45%) As of 09:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPSC vs. PRME, INMB, TLSA, MOLN, ELDN, CTMX, OGI, INBX, PRQR, and HURAShould you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Prime Medicine (PRME), INmune Bio (INMB), Tiziana Life Sciences (TLSA), Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), CytomX Therapeutics (CTMX), Organigram (OGI), Inhibrx (INBX), ProQR Therapeutics (PRQR), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. Century Therapeutics vs. Prime Medicine INmune Bio Tiziana Life Sciences Molecular Partners Eledon Pharmaceuticals CytomX Therapeutics Organigram Inhibrx ProQR Therapeutics TuHURA Biosciences Prime Medicine (NYSE:PRME) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings. Do insiders and institutionals believe in PRME or IPSC? 70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 23.5% of Prime Medicine shares are owned by insiders. Comparatively, 6.8% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to PRME or IPSC? In the previous week, Prime Medicine had 12 more articles in the media than Century Therapeutics. MarketBeat recorded 19 mentions for Prime Medicine and 7 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.36 beat Prime Medicine's score of 0.02 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, PRME or IPSC? Prime Medicine has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Do analysts rate PRME or IPSC? Prime Medicine presently has a consensus price target of $11.80, suggesting a potential upside of 912.88%. Century Therapeutics has a consensus price target of $4.20, suggesting a potential upside of 624.64%. Given Prime Medicine's higher probable upside, research analysts clearly believe Prime Medicine is more favorable than Century Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86Century Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PRME or IPSC more profitable? Prime Medicine has a net margin of 0.00% compared to Century Therapeutics' net margin of -4,837.73%. Century Therapeutics' return on equity of -61.66% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Century Therapeutics -4,837.73%-61.66%-31.78% Which has better earnings and valuation, PRME or IPSC? Century Therapeutics has higher revenue and earnings than Prime Medicine. Century Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$3.85M39.77-$198.13M-$1.61-0.72Century Therapeutics$114.90M0.43-$136.67M-$0.29-2.00 Does the MarketBeat Community believe in PRME or IPSC? Century Therapeutics received 13 more outperform votes than Prime Medicine when rated by MarketBeat users. Likewise, 70.49% of users gave Century Therapeutics an outperform vote while only 65.22% of users gave Prime Medicine an outperform vote. CompanyUnderperformOutperformPrime MedicineOutperform Votes3065.22% Underperform Votes1634.78% Century TherapeuticsOutperform Votes4370.49% Underperform Votes1829.51% SummaryCentury Therapeutics beats Prime Medicine on 11 of the 19 factors compared between the two stocks. Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPSC vs. The Competition Export to ExcelMetricCentury TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.94M$2.93B$5.37B$8.39BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.3130.5026.8419.71Price / Sales0.43400.15392.34117.39Price / CashN/A168.6838.2534.62Price / Book0.193.286.794.50Net Income-$136.67M-$72.17M$3.23B$248.18M7 Day Performance12.02%2.96%1.53%0.20%1 Month Performance7.33%3.25%10.06%12.37%1 Year Performance-82.44%-28.29%16.72%7.04% Century Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPSCCentury Therapeutics2.4917 of 5 stars$0.58-3.4%$4.20+624.6%-80.5%$49.94M$114.90M-0.31170Earnings ReportAnalyst RevisionGap UpPRMEPrime Medicine3.7038 of 5 stars$1.34+3.1%$13.14+880.8%-85.5%$175.76M$3.85M-0.65234News CoverageAnalyst ForecastAnalyst RevisionGap DownINMBINmune Bio1.9394 of 5 stars$7.64+9.6%$22.80+198.4%-29.4%$175.60M$14,000.00-3.5010Gap UpTLSATiziana Life Sciences1.0761 of 5 stars$1.50-4.5%N/A+73.2%$175.27MN/A0.008Gap UpMOLNMolecular Partners1.9444 of 5 stars$4.28+4.4%$12.00+180.4%+10.6%$172.81M$4.97M-1.99180Positive NewsEarnings ReportAnalyst RevisionELDNEledon Pharmaceuticals2.1537 of 5 stars$2.87-0.7%$12.50+335.5%+1.9%$171.86MN/A-1.4310News CoveragePositive NewsAnalyst RevisionGap UpCTMXCytomX Therapeutics4.2375 of 5 stars$2.13+129.4%$4.25+99.5%+9.1%$171.72M$138.10M12.53170Analyst RevisionGap DownHigh Trading VolumeOGIOrganigram0.2599 of 5 stars$1.28+8.5%N/A-30.2%$171.31M$166.12M-3.37860High Trading VolumeINBXInhibrx1.8924 of 5 stars$11.71+4.7%N/A-61.6%$169.51M$200,000.000.00166PRQRProQR Therapeutics3.1911 of 5 stars$1.59-1.2%$8.75+450.3%-9.5%$167.29M$18.91M-4.97180HURATuHURA BiosciencesN/A$3.82-4.3%$12.67+231.6%N/A$166.86MN/A0.00N/AEarnings ReportAnalyst Revision Related Companies and Tools Related Companies PRME Alternatives INMB Alternatives TLSA Alternatives MOLN Alternatives ELDN Alternatives CTMX Alternatives OGI Alternatives INBX Alternatives PRQR Alternatives HURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPSC) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
